Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, Placebo-controlled, Phase IIa Dose-ranging Study to Assess the Safety, Pharmacokinetics, and Tolerability of Multiple Doses of Sodium Nitrite in Diabetic Patients With Peripheral Arterial Disease (PAD) - SONIC

Next Previous
Trial Profile

A Randomized, Double-blinded, Placebo-controlled, Phase IIa Dose-ranging Study to Assess the Safety, Pharmacokinetics, and Tolerability of Multiple Doses of Sodium Nitrite in Diabetic Patients With Peripheral Arterial Disease (PAD) - SONIC

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium nitrite (Primary)
  • Indications Diabetic complications; Peripheral arterial disorders
  • Focus Adverse reactions
  • Acronyms SONIC
  • Sponsors TheraVasc

Most Recent Events

  • 13 Apr 2023 According to a JanOne media release, Dr.Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Sat, Apr 15 on the topic of Innovation in Pain Medicine and will be discussing the drug development programs (JAN 101 and JAN123) at JanOne.
  • 16 Sep 2020 According to a JanOne media release, JAN101 demonstrated positive results in this trial.
  • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top